Alemtuzumab induction in renal transplantation

New England Journal of Medicine

Volumn 364, Issue 20, 2011, Pages 1909-1919

  Hanaway, Michael J ^a   Woodle, E Steve ^b   Mulgaonkar, Shamkant ^c   Peddi, V Ram ^d   Kaufman, Dixon B ^e   First, M Roy ^f   Croy, Richard ^f   Holman, John ^f  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c St Barnabas Health System   (United States)

^d CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^e UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^f ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; GLUCOCORTICOID; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; AGED; ARTICLE; B CELL LYMPHOMA; BK VIRUS INFECTION; BLOOD TOXICITY; CANDIDIASIS; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; EPSTEIN BARR VIRUS INFECTION; FEMALE; GASTROINTESTINAL SYMPTOM; HERPES SIMPLEX; HERPES ZOSTER; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; INFECTION; KIDNEY BIOPSY; KIDNEY DYSFUNCTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTICENTER STUDY; NEGRO; NEOPLASM; PRIORITY JOURNAL; PROSPECTIVE STUDY; RABBIT; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SINGLE DRUG DOSE; SKIN CANCER; STRATIFICATION; THROMBOCYTOPENIA; VIRUS INFECTION;

EID: 79956189911     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1009546     Document Type: Article

References (23)

1. 2008 OPTN/SRTR annual report: transplant data 1998-2007. (http://optn.transplant.hrsa.gov/ar2008.)
2. Calne R, Moffatt SD, Friend PJ, et al. Campath 1H allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation 1999;68:1613-6.
3. Knechtle SJ, Fernandez LA, Pirsch JD, et al. Campath-1H in renal transplantation: the University of Wisconsin experience. Surgery 2004;136:754-60. (Pubitemid 39311300)
4. Kaufman DB, Leventhal JR, Axelrod D, Gallon LG, Parker MA, Stuart FP. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction - long-term results. Am J Transplant 2005;5:2539-48.
5. Margreiter R, Klempnauer J, Neuhaus P, Muehlbacher F, Boesmueller C, Calne RY. Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a randomized trial. Am J Transplant 2008;8:1480-5. (Pubitemid 351989498)
6. Vanrenterghem Y, LeBranchu Y, Hene R, Oppenheimer F, Ekberg H. Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. Transplantation 2000;70:1352-9.
7. Steroid Withdrawal Study Group. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil - a prospective, randomized study. Transplantation 1999;68:1865-74.
8. Matas AJ, Ramcharan T, Paraskevas S, et al. Rapid discontinuation of steroids in living donor kidney transplantation: a pilot study. Am J Transplant 2001;1:278-83. (Pubitemid 33674172)
9. Gallon LG, Winoto J, Leventhal JR, Parker MA, Kaufman DB. Effect of prednisone versus no prednisone as part of maintenance immunosuppression on longterm renal transplant function. Clin J Am Soc Nephrol 2006;1:1029-38.
10. Vincenti F, Ramos E, Brattstrom C, et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001;71:1282-7. (Pubitemid 32507148)
11. Woodle ES, First MR, Pirsch J, et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term corticosteroid therapy. Ann Surg 2008;248:564-77.
12. Boardman RE, Alloway RR, Alexander JW, et al. African American renal transplant recipients benefit from early corticosteroid withdrawal under modern immunosuppression. Transplant Proc 2005;37:814-6. (Pubitemid 40590710)
13. Woodle ES, Alloway RR, Buell JF, et al. Multivariate analysis of risk factors for acute rejection in early corticosteroid cessation regimens under modern immunosuppression. Am J Transplant 2005;5:2740-4.
14. Noel C, Abramowicz D, Durand D, et al. Daclizumab versus antithymocyte globulin in high-immunologic risk renal transplant recipients. J Am Soc Nephrol 2009;20:1385-92.
15. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983;70:659-63.
16. Almond PS, Matas A, Gillingham K, et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993;55:752-7. (Pubitemid 23122041)
17. Ferguson R. Acute rejection episodes - best predictor of long-term primary cadaveric renal transplant survival. Clin Transplant 1994;8:328-31. (Pubitemid 24163500)
18. Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006;355:1967-77. (Pubitemid 44708016)
19. Brennan DC, Schnitzler MA. Long-term results of rabbit antithymocyte globulin and basiliximab induction. N Engl J Med 2008;359:1736-8.
20. Huang E, Cho YW, Hayashi R, Bunnapradist S. Alemtuzumab induction in deceased donor renal transplantation. Transplantation 2007;84:821-8. (Pubitemid 351338941)
21. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up. Clin Transplant 2008;22:200-10. (Pubitemid 351420014)
22. Ciancio G, Burke GW, Gaynor J, et al. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenylate mofetil, and steroid dosing, and newer immunosuppressive monitoring. Transplantation 2005;80:457-65. (Pubitemid 41209412)
23. Pascual J, Pirsch J, Torrealba J, et al. Antibody-mediated rejection (AMR) in renal allograft recipients treated with alemtuzumab induction. Am J Transplant 2008;8:Suppl 2:237. abstract.